Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Gluconolactone | hsa00220 | Arginine biosynthesis | 2.21E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | Gluconolactone | hsa00230 | Purine metabolism | 4.02E-02 | 2 | P31350, P21589 | RRM2, NT5E | More | | Gluconolactone | hsa00240 | Pyrimidine metabolism | 2.54E-04 | 3 | P31350, P21589, P04818 | RRM2, NT5E, TYMS | More | | Gluconolactone | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.21E-02 | 2 | P49448, P15104 | GLUD2, GLUL | More | | Gluconolactone | hsa00500 | Starch and sucrose metabolism | 3.88E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Gluconolactone | hsa00640 | Propanoate metabolism | 1.63E-02 | 2 | Q02252, P21953 | ALDH6A1, BCKDHB | More | | Gluconolactone | hsa00730 | Thiamine metabolism | 3.79E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Gluconolactone | hsa00910 | Nitrogen metabolism | 2.21E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | Gluconolactone | hsa00970 | Aminoacyl-tRNA biosynthesis | 4.16E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | | Gluconolactone | hsa01523 | Antifolate resistance | 6.06E-03 | 2 | Q92820, P04818 | GGH, TYMS | More | | Gluconolactone | hsa03010 | Ribosome | 4.16E-02 | 2 | P46777, P50914 | RPL5, RPL14 | More | | Gluconolactone | hsa04064 | NF-kappa B signaling pathway | 2.69E-02 | 9 | P10415, O00463, P01375, Q04759, Q13077, Q16548, Q8WV28, P24522, P09341 | BCL2, TRAF5, TNF, PRKCQ, TRAF1, BCL2A1, BLNK, GADD45A, CXCL1 | More | | Gluconolactone | hsa04071 | Sphingolipid signaling pathway | 2.06E-02 | 7 | Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | Gluconolactone | hsa04080 | Neuroactive ligand-receptor interaction | 2.54E-02 | 7 | P08311, Q15722, Q9H228, P21462, P21730, Q16581, P35318 | CTSG, LTB4R, EDG8, FPR1, C5AR1, C3AR1, ADM | More | | Gluconolactone | hsa04110 | Cell cycle | 2.34E-02 | 3 | P06493, O60566, P33981 | CDK1, BUB1B, TTK | More | | Gluconolactone | hsa04115 | p53 signaling pathway | 3.34E-02 | 2 | P31350, P06493 | RRM2, CDK1 | More | | Gluconolactone | hsa04218 | Cellular senescence | 2.19E-02 | 6 | P01106, Q9H422, P42338, Q16539, P24522, P30304 | MYC, HIPK3, PIK3CB, MAPK14, GADD45A, CDC25A | More | | Gluconolactone | hsa04340 | Hedgehog signaling pathway | 1.43E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Gluconolactone | hsa04370 | VEGF signaling pathway | 4.16E-02 | 2 | P42338, Q16539 | PIK3CB, MAPK14 | More | | Gluconolactone | hsa04613 | Neutrophil extracellular trap formation | 1.37E-02 | 12 | O60603, P05164, P08246, Q9UM07, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Gluconolactone | hsa04621 | NOD-like receptor signaling pathway | 2.64E-02 | 10 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, TNF, CXCL1, DEFA4 | More | | Gluconolactone | hsa04657 | IL-17 signaling pathway | 1.28E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Gluconolactone | hsa04658 | Th1 and Th2 cell differentiation | 3.21E-03 | 9 | Q04759, P20963, P09693, Q16539, Q14765, P42226, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, STAT4, STAT6, GATA3, TBX21, HLA-DOB | More | | Gluconolactone | hsa04659 | Th17 cell differentiation | 3.33E-03 | 12 | Q04759, Q16539, P01730, P06239, P42226, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, CD4, LCK, STAT6, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Gluconolactone | hsa04660 | T cell receptor signaling pathway | 1.07E-02 | 9 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, MAPK14, GSK3B | More | | Gluconolactone | hsa04724 | Glutamatergic synapse | 1.17E-02 | 4 | P48058, P43003, P50151, P15104 | GRIA4, SLC1A3, GNG10, GLUL | More | | Gluconolactone | hsa04973 | Carbohydrate digestion and absorption | 7.81E-03 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Gluconolactone | hsa05012 | Parkinson disease | 3.20E-02 | 4 | P60604, O60282, Q13509, P68371 | UBE2G2, KIF5C, TUBB3, TUBB2C | More | | Gluconolactone | hsa05020 | Prion disease | 4.79E-02 | 4 | O60282, Q13509, P68371, P14598 | KIF5C, TUBB3, TUBB2C, NCF1 | More | | Gluconolactone | hsa05135 | Yersinia infection | 4.60E-02 | 4 | P06239, Q16539, P42338, P01730 | LCK, MAPK14, PIK3CB, CD4 | More | | Gluconolactone | hsa05145 | Toxoplasmosis | 3.96E-02 | 2 | P28068, Q16787 | HLA-DMB, LAMA3 | More | | Gluconolactone | hsa05150 | Staphylococcus aureus infection | 4.37E-02 | 6 | P21730, P21462, O75015, P13765, Q16581, P12838 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, DEFA4 | More | | Gluconolactone | hsa05163 | Human cytomegalovirus infection | 2.62E-02 | 6 | P42338, P50151, P01106, P14778, Q13651, Q16539 | PIK3CB, GNG10, MYC, IL1R1, IL10RA, MAPK14 | More | | Gluconolactone | hsa05165 | Human papillomavirus infection | 2.01E-02 | 3 | Q16787, Q02930, Q13315 | LAMA3, CREB5, ATM | More | | Gluconolactone | hsa05166 | Human T-cell leukemia virus 1 infection | 2.41E-03 | 12 | P01106, Q02930, O60566, P14778, P27930, P07766, P42338, P28068, P42773, P06239, Q13315, P01730 | MYC, CREB5, BUB1B, IL1R1, IL1R2, CD3E, PIK3CB, HLA-DMB, CDKN2C, LCK, ATM, CD4 | More | | Gluconolactone | hsa05169 | Epstein-Barr virus infection | 4.32E-02 | 11 | P13765, O00463, P16070, P10415, Q16539, P24522, Q8WV28, P01375, O60603, P09693, P20963 | HLA-DOB, TRAF5, CD44, BCL2, MAPK14, GADD45A, BLNK, TNF, TLR2, CD3G, CD247 | More | | Gluconolactone | hsa05202 | Transcriptional misregulation in cancer | 8.07E-04 | 14 | Q15532, P14780, P27930, Q16548, Q13077, Q15652, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P24522 | SS18, MMP9, IL1R2, BCL2A1, TRAF1, JMJD1C, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, GADD45A | More | | Gluconolactone | hsa05213 | Endometrial cancer | 3.83E-02 | 3 | P01106, P42338, P24522 | MYC, PIK3CB, GADD45A | More | | Gluconolactone | hsa05217 | Basal cell carcinoma | 1.43E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Gluconolactone | hsa05224 | Breast cancer | 1.64E-02 | 4 | P42338, P01106, Q92837, P24522 | PIK3CB, MYC, FRAT1, GADD45A | More | | Gluconolactone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.28E-02 | 5 | P42338, P07766, P06239, Q16539, P01730 | PIK3CB, CD3E, LCK, MAPK14, CD4 | More | | Gluconolactone | hsa05321 | Inflammatory bowel disease | 7.62E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P42226, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, STAT6, GATA3 | More | | Gluconolactone | hsa05418 | Fluid shear stress and atherosclerosis | 2.60E-02 | 5 | Q16539, P42338, P10599, P14778, P27930 | MAPK14, PIK3CB, TXN, IL1R1, IL1R2 | More | | |